Start the conversation
Shares of blood-cancer biotech Pharmacyclics Inc. (Nasdaq: PCYC) soared to an all-time high of $154.89 on Friday after the Sunnyvale, Calif.-based company reported fourth-quarter financial results that absolutely crushed Wall Street estimates.
The stock has rocketed through past resistance points and raced to this new high. Although the stock later backtracked a bit later in the day, Pharmacyclics shares are up 427% since we recommended them in the April 2012 special report "The Biotech Buyout Binge." That makes the stock one of the 23 recommendations that have doubled or better since we launched Private Briefing a bit more than two years ago.
This is premium content for Private Briefing subscribers only.